Thymosin Alpha-1 Dosing Protocol: Clinical Research
Also known as: Zadaxin, Thymalfasin, T-Cell Immune Modulator
Studied in published research — not a medical recommendation. Primary protocol (Immune Enhancement Protocol): 1.6 mg, Twice weekly.
Twice weekly
Research-reported range; the linked study used a different dose or units.
Subcutaneous
Published peer-reviewed research & clinical protocols
No verified human half-life on file for this compound
A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.
All U-100: 100 units = 1 mL. 3 doses in the vial at the low end.
Save Thymosin Alpha-1 (Tα1) to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.
Thymosin Alpha-1 (Tα1) supplier & $/mg comparison.
At a Glance · 2026 FDA / 503A / WADA / Evidence Profile
What is a Peptide?
A short chain of amino acids (2-50) linked by peptide bonds. Smaller than proteins. Your body produces thousands of peptides naturally as signaling molecules that regulate everything from appetite to healing. Therapeutic peptides mimic or enhance these natural signals.
Thymosin Alpha-1 (Tα1) is the same active compound as Zadaxin (SciClone Pharmaceuticals). Not FDA approved in the US.
EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. Thymosin Alpha-1 (Tα1) is not FDA approved for human use (unless specified above). This information does not constitute medical advice.
Overview
Thymosin Alpha-1 is a peptide fragment derived from prothymosin alpha. It has been studied for its immunomodulatory properties and effects on T-cell function.
Mechanisms of Action
- Enhances T-cell differentiation
- Modulates cytokine production
- Supports dendritic cell maturation
- Regulates immune response balance
Research Protocols
Systemic Inflammation, Tissue Repair & Immune Biomarker Panel (Thymosin Alpha-1 (Tα1))
Objective inflammatory, hematologic, and trace-mineral markers to quantify connective-tissue recovery, cytokine resolution, and organ safety.
hs-CRP (High-Sensitivity C-Reactive Protein)
Day 0 + Wk 6–8Why track at baseline: Quantifies baseline systemic IL-6/NF-κB inflammatory burden from tendon, joint, gut, or vascular injury.
Week 6–8 check: Target <1.0 mg/L (optimal <0.5 mg/L) by Week 6–8 as tissue inflammation resolves.
ESR (Sedimentation Rate) & Ferritin
Day 0 + Wk 6–8Why track at baseline: Tracks chronic connective-tissue and autoimmune/mucosal inflammatory activity alongside iron stores.
Week 6–8 check: Downward trend in ESR confirming structural resolution rather than temporary analgesic masking.
CBC with Differential (WBC, Neutrophil/Lymphocyte Ratio)
Day 0 + Wk 6–8Why track at baseline: Evaluates innate/adaptive immune balance (especially for Thymosin Alpha-1, Thymosin Beta-4, LL-37 & KPV).
Week 6–8 check: Balanced lymphocyte count and improved Neutrophil-to-Lymphocyte Ratio (NLR 1.2–2.0).
CMP (Liver/Kidney) + Serum Copper & Zinc Ratio
Day 0 + Wk 6–8Why track at baseline: Verifies baseline hepatic/renal function and checks Copper:Zinc balance before GHK-Cu / GLOW / KLOW protocols.
Week 6–8 check: Maintain 1:1 to 1.2:1 Zinc-to-Copper equilibrium and normal transaminases/creatinine.
Related Studies
Aging and Thymosin Alpha-1.
Human StudyIt represents a promising therapeutic approach to counteract age-related immune dysfunction and inflammation, potentially by slowing the aging process. Further research is needed to validate its long-term efficacy and safety in geriatrics.
Limitations: No placebo control reported. Review article — no new primary data.
Both exogenously supplied and adenovirus-produced Tα1 orchestrate TAM reprogramming and enhance the antitumor efficacy of ADV via CD8+ T cells, showing promising prospects for clinical translation. Our findings provide inspiration for improving oncolytic adenovirus combination therapy and designing oncolytic engineered adenoviruses.
Limitations: No placebo control reported.
Although PDD presents challenges such as hit validation and target deconvolution, significant achievements have been reached in the era of big data. This article explores the experiences of researchers testing the effect of a thymic peptide hormone, thymosin alpha-1, in preclinical and clinical settings and discuss how its therapeutic utility in the precision medicine era can be accommodated within the PDD framework.
Limitations: Animal study only — human translation uncertain. Review article — no new primary data.
More high-quality randomised controlled trials are needed to further confirm Thymosin alpha 1 efficacy. Key Words: Thymosin alpha 1, Efficacy, Acute exacerbation of chronic obstructive pulmonary disease, Meta-analysis.
Limitations: No placebo control reported. Review article — no new primary data.
Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials.
Human StudyContrary to the FDA's restriction on Tα1 and 21 additional peptides in 2023, our analysis reveals consistent evidence of Tα1's safety and efficacy. The peptide has demonstrated significant effectiveness in treating various conditions, including COVID-19, autoimmune disorders, and cancer.
Limitations: No placebo control reported. Review article — no new primary data.
A total of 49 patients were included in this analysis. Compared with control patients, the incidence of clinical recovery was higher for treated patients with either baseline low-flow oxygen (subdistribution hazard ratio, 1.48 [95% confidence interval, .68-3.25]) or baseline high-flow oxygen (1.28 [.35-4.63]), although neither difference was significant.
Limitations: Preliminary/pilot study — needs larger trials. No placebo control reported.
For treatment of malignancies, the combination of Tα-1 and chemotherapy has a strong synergistic effect by enhancing the anti-tumor immune response. On the basis of the pleiotropic effect of Tα-1 on immune cells and the promising results of preclinical studies, Tα-1 may be a favorable immunomodulator to enhance the curative effect and decrease immune-related adverse events of immune checkpoint inhibitors to develop novel cancer therapies.
Limitations: No placebo control reported.
In severe sepsis, for example, sepsis-induced immunosuppression is increasingly recognized as the overriding immune dysfunction in these vulnerable patients [4] and there is now agreement that many patients with severe sepsis survive the first critical hours of the syndrome but eventually die later due to patients' immunosuppression which make the system difficulty to fight the primary bacterial infection, decreased resistance to secondary nosocomial infections, and reactivation of viral infections [5]. Tα1 has been shown to restore immune functions and help to reduce mortality in patients with severe sepsis.
Limitations: No placebo control reported.
Pooled data from 8 studies indicated that moderate to critical Covid-19 patients who were receiving thymosin alpha-1 therapy had significantly lower mortality from COVID-19 (RR 0.59; 95% CI 0.37-0.93, p = 0.02, I2 = 84%), but without any difference in the needs for mechanical ventilation (RR 0.83; 95% CI 0.48-1.44, p = 0.51, I2 = 74%) and hospital length of stay (MD 2.32; 95% CI - 0.93, 5.58, p = 0.16, I2 = 94%) compared to placebo. The benefits of thymosin alpha-1 on the mortality rate were significantly affected only by sample size (p = 0.0000) and sex (p = 0.0117).
Limitations: Review article — no new primary data.
Thymosin α-1 Reverses M2 Polarization of Tumor-Associated Macrophages during Efferocytosis.
Human StudyIn conclusion, Tα-1 improved the curative effect of chemotherapy by reversing M2 polarization of efferocytosis-activated macrophages, suggesting that Tα-1 injection immediately after chemotherapy may contribute to highly synergistic antitumor effects in patients with breast cancer. SIGNIFICANCE: Thymosin α-1 improves the curative effect of chemotherapy by reversing efferocytosis-induced M2 polarization of macrophages via activation of a TLR7/SHIP1 axis.
Limitations: No placebo control reported.
All crude outcomes, including non-recovery rate (65/306 vs. 290/1,976, p = 0.003), in-hospital mortality rate (62/306 vs.
Limitations: No placebo control reported.
In this review, we discuss key literature on the background knowledge and current clinical uses of thymosin alpha 1. Considering the known biochemical properties including antibacterial and antiviral properties, time-honored applications, and the new promising findings regarding the use of thymosin, we believe that thymosin alpha 1 deserves further investigation into its antiviral properties and possible repurposing as a treatment against severe acute respiratory syndrome coronavirus-2.
Limitations: No placebo control reported. Review article — no new primary data.
This study also calls into question the autophagy modulator cysteamine, since no rescue of mutant CFTR function was detected following treatment with cysteamine, while deleterious effects were observed when bronchial epithelia were exposed to cysteamine plus the antioxidant food supplement EGCG. Although these studies do not exclude the possibility of beneficial immunomodulatory effects of thymosin α-1, they do not support its utility as a corrector of F508del-CFTR.
Limitations: No placebo control reported.
Also, the present studies on Tα1 treatment are not able to focus on the immunosuppressive individuals. We believe that selecting septic patients with immunosuppression will be more likely to reveal the efficacy of Tα1 in future trials.
Limitations: No placebo control reported. Review article — no new primary data.
EXPERT OPINION: Low serum Ta1 levels are predictive and/or associated with different pathological conditions. In case of Ta1 treatment, it is crucial to know the patient's baseline serum Ta1 level to establish effective treatment protocols and monitor their effectiveness over time.
Limitations: No placebo control reported. Review article — no new primary data.
From thymus to cystic fibrosis: the amazing life of thymosin alpha 1. (Expert opinion on biological therapy, 2019)
Limitations: Animal study only — human translation uncertain.
Extensive studies in both the preclinical and clinical setting will be summarized in the subsequent sections. These studies have demonstrated improvements in immune system cell subsets and the potential of Ta1 for the treatment of a range of diseases.
Limitations: No placebo control reported. Review article — no new primary data.
This review reports the present knowledge on the in vitro and in vivo studies concerning the use of thymosin alpha 1 in HIV-1 infection. Recent findings and future perspectives of therapeutic intervention are discussed.
Limitations: No placebo control reported. Review article — no new primary data.
Structures of Thymosin Proteins.
Human StudyThe differing structures of thymosin alpha and thymosin beta proteins have been studied by circular dichroism, nuclear magnetic resonance, and crystallographic methods in order to better understand the role of these proteins. In this structural biology review the structures of prothymosin, parathymosin, thymosin alpha-1, and several beta thymosin proteins, in both native states and under secondary structure-inducing conditions are discussed.
Limitations: No placebo control reported. Review article — no new primary data.
Most of the combination therapy of Tα-1 plus either lamivudine or IFN-α showed better effects on HBV DNA suppression and HBeAg seroconversion. Presently, clinical studies of Tα-1 combined with entecavir on the treatment of HBV-cirrhosis are ongoing.
Limitations: No placebo control reported.
In the most recent clinical trials Tα1 has been used at higher doses than those commonly used in the past showing a direct proportionality between the dose and the effect. The safety profile of Tα1 is excellent and it is virtually devoid of toxicity.
Limitations: No placebo control reported. Review article — no new primary data.
Three populations were.
Limitations: No placebo control reported.
Several studies were conducted and showed that Talpha1 ameliorate the performanc of influenza vaccination in elderly and subjects at risk. Although further studies on co-adjuvants are necessary, the future prospects of producing ever more efficacious influenza vaccines appear very promising.
Limitations: No placebo control reported. Review article — no new primary data.
It has been shown to trigger maturational events in lymphocytes, to augment T-cell function, and to promote reconstitution of immune defects. Studies are underway in both monotherapy and combination therapy with thymalfasin and interferon and results are promising.
Limitations: No placebo control reported. Review article — no new primary data.
It has been shown to trigger maturational events in lymphocytes, to augment T-cell function, and to promote reconstitution of immune defects. Studies are underway in both monotherapy and combination therapy with thymalfasin and interferon and results are promising.
Limitations: No placebo control reported. Review article — no new primary data.
Thymosin alpha-1.
Human StudyClinical trials of TA1 for chronic hepatitis B or C have had mixed results. TA1 may be useful as monotherapy for hepatitis B or in combination with IFN-alpha 2b for hepatitis C, but its effects on morbidity and mortality remain to be seen.
Limitations: Review article — no new primary data.
Thymic endocrinology.
Human StudyOur work to reverse thymic involution in hydrocortisone-treated, aged mice with interleukins, thymosin alpha 1, and zinc will be reviewed. Recent efforts to treat successfully immune deficiency in aged and cancer-bearing humans will be presented.
Limitations: No placebo control reported. Review article — no new primary data.
T-cell adjuvants.
Human StudyFinally, "thymomimetic" peptides like thymosin alpha 1 or drugs like levamisole or isoprinosine alone or in conjunction with interleukins may augment TH-1 and DTH responses. These approaches are seeing increasing emphasis in new treatment strategies for cancer and infections like HIV.
Limitations: No placebo control reported. Review article — no new primary data.
Clinical applications of thymosin alpha-1.
Human StudyClinical applications of thymosin alpha-1. (Cancer investigation, 1994)
Limitations: No placebo control reported. Review article — no new primary data.
Thymic endocrinology.
Animal StudyThymic stromal cells contribute, at minimum, IL1. These various interleukin and thymic hormone influences can be envisioned to operate in a synergistic interactive network to carry the evolving T-cell through its stepwise development to a mature T-cell.(ABSTRACT TRUNCATED AT 250 WORDS).
Limitations: Animal study only — human translation uncertain. Review article — no new primary data.
Community Outcomes
Community Data Coming Soon
Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!
Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.
Important Warnings
- •Prescription drug in some countries
- •Consult healthcare provider
Where to get Thymosin Alpha-1 (Tα1), baseline labs & clinician oversight.
Ascension Peptides (US Vials)
MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.
SwissChems & Limitless Biotech
Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).
Superpower Labs & 503A Telehealth
Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.
Where to buy Thymosin Alpha-1 (Tα1): best verified price
Prices checked Nov 11, 2026 · sorted by $/mg · RUO
- 1. Ascension Peptides — $3.55/mg (10mg Lyophilized Vial, $35.50)
- 2. Polaris Peptides — $6.50/mg (10mg vial, $65.00)
- 3. Elite Research USA — $7.80/mg (10mg vial, $78.00)
Where is the cheapest place to buy Thymosin Alpha-1 (Tα1)?
As of Nov 11, 2026, the lowest verified US domestic single-vial price we found is Ascension Peptides at $3.55/mg (10mg Lyophilized Vial, $35.50 after the 50% new-customer partner-link discount). We compared 11 US suppliers with live, checked prices.
How much does Thymosin Alpha-1 (Tα1) cost per mg?
Verified US domestic prices currently range from $3.55/mg to $14.90/mg depending on supplier and vial size. Larger vials usually lower the $/mg.
How are these prices verified?
Each price is read from the supplier's own product page or store data and divided by the vial's mg. Suppliers we could not verify are left out rather than estimated. Tables sort strictly by $/mg, never by partner status. Prices are re-checked weekly on our price index.
Is Thymosin Alpha-1 (Tα1) approved for human use?
Products from these suppliers are sold for laboratory research use only (RUO). This page is an educational price reference, not medical advice.
All compounds $/mgWeekly $/mg price indexReconstitution calculatorFree cheat sheet
Peptide Reconstitution & U-100 Syringe Cheat Sheet
Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.
Trusted Voices
X/Twitter accounts discussing this peptide
Related Peptides
More immunity peptides
Thymalin
Thymalin is a polypeptide complex isolated from the thymus g...
LL-37 (Cathelicidin)
LL-37 is the only known human cathelicidin antimicrobial pep...
Thymulin (Nonapeptide)
Thymulin is a nonapeptide hormone produced by thymic epithel...
VIP (Vasoactive Intestinal Peptide)
VIP (Vasoactive Intestinal Peptide) is a 28-amino acid neuro...
KPV
KPV is a tripeptide (Lysine-Proline-Valine) that is a fragme...
Popular Stacks
Vendor vs vendor: price per mg
Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.
- Ascension vs SwissChems (3 shared compounds)
- Elite vs SwissChems (3 shared compounds)
- Elite vs Ascension (26 shared compounds)
- Protide vs SwissChems (3 shared compounds)
- Protide vs Ascension (6 shared compounds)
- Ameano vs SwissChems (3 shared compounds)
- Ameano vs Ascension (4 shared compounds)
- Swift vs Ascension (23 shared compounds)
- BioLongevity vs Ascension (16 shared compounds)
- Peptyes vs SwissChems (3 shared compounds)
- Peptyes vs Elite (20 shared compounds)
- Peptyes vs Swift (17 shared compounds)
- Peptyes vs Pure (17 shared compounds)
- Peptyes vs Ascension (20 shared compounds)
Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →
Common questions
How many peptides are in the database?
100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.
Where can I compare peptide prices?
Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.